The short answer
Who did what in bringing Covishield into production? The history is a chain of research, licensing, manufacturing, authorisation and procurement. These functions depended on one another, but belonged to different organisations and decisions.
Chronology
A timeline of the turning points
Manufacturing licence
AstraZeneca announces an SII agreement for designated low- and middle-income markets.
Indian regulatory decision
DCGI permits restricted emergency use subject to conditions and continuing trial work.
First domestic shipments
Serum records initial Covishield shipments leaving its facility.
WHO listing
WHO lists the Serum-manufactured Oxford–AstraZeneca product for emergency use.
Supply interruption and return
India’s domestic crisis interrupts exports; later reporting records gradual resumption.
Research ownership and manufacturing responsibility differed
Oxford developed the vaccine technology, while AstraZeneca took development and licensing responsibilities. Serum’s agreement added industrial production and supply for designated markets. The Covishield name identified the version manufactured by SII, not a new invention by its chief executive.
That division matters when crediting people. Adar Poonawalla represented a manufacturer capable of committing facilities and resources. Research scientists, clinical investigators, production specialists and regulators performed different tasks. A recognisable business leader cannot substitute for the institutional chain that brought the product into use.
June commitments were made before the outcome was known
AstraZeneca’s 4 June 2020 announcement described a licensing agreement with SII for large-scale supply. It also acknowledged that the candidate might not work and that production capacity was being developed at risk. The announced dose figures were commitments and intentions, rather than evidence that those doses had already been manufactured or delivered.
Preparing factories before final clinical and regulatory decisions could shorten the time needed after a successful outcome. It also created financial and operational exposure. The historical point is the sequencing of commitments under uncertainty; the original release should not be rewritten as if all later permissions were already assured.
Sources for this section: [7]
India’s permission and WHO’s listing served different purposes
On 3 January 2021 DCGI announced restricted emergency permission for Covishield after review of overseas and Indian data. The release stated that the Indian trial would continue and that permission carried regulatory conditions. This was the relevant national authorisation, not an unrestricted guarantee about every future circumstance.
WHO’s 15 February listing was a separate international assessment supporting emergency-use procurement, including the COVAX system. One date cannot replace the other. Nor should historical authorisations be used here to prescribe present treatment or imply that later regulatory assessments could never change.
A licensed and authorised product still needed delivery
Serum recorded first domestic shipments leaving its plant on 12 January. Dispatch was an operational milestone after the authorisation decision. It required finished stock, release procedures, packaging, transport and coordination with the institutions receiving doses.
Procurement and distribution remained separate from manufacturing capacity. A dose leaving a factory was not yet a completed vaccination, and a supply promise did not establish arrival in every intended country. Keeping those units distinct prevents production figures from becoming unsupported claims about population coverage or health outcomes.
The 2021 crisis exposed conflicting demands
India’s severe wave increased domestic demand and led to interruption of vaccine exports. Reporting in May included Poonawalla’s defence of earlier exports and his explanation of production constraints. His response belongs alongside the shortages and unmet international expectations, rather than being treated as an independent verdict on the allocation choices.
Reuters’s October account described gradual export resumption. The sequence shows why licensing and factory capacity were necessary but insufficient: government policy, supplies, procurement schedules and changing epidemiological circumstances also shaped delivery. This guide documents institutional history, without offering individual medical advice or a current vaccination recommendation.
Continue the chronology
Related history guides
The manufacturing enterprise before Covishield
Understand the earlier company and founder whose accumulated capabilities preceded the pandemic.
Read the timeline1995The distinct Cadila companies
Keep another pharmaceutical group’s organisational identities separate from product authorisations.
Read the timelineBiography context
Explore Oxford, United Kingdom; Pune, India; international procurement networks through connected lives
Connected biographies
The manufacturer’s executive participant
1981–present
Adar Poonawalla
Serum Institute of India chief executiveAdar Poonawalla joined the Serum Institute of India in 2001 and became chief executive in 2011. His father Cyrus founded the company in 1966. Adar’s work has centred on manufacturing, international supply and partnerships, including the production of the Oxford–AstraZeneca vaccine as Covishield during the pandemic.Read biographyQuick answers
Common questions
- Was the June 2020 licence an approval to vaccinate people?
- No. It was a manufacturing and supply agreement. Regulatory permission came through separate decisions.
- Were Indian permission and WHO listing simultaneous?
- No. DCGI’s decision was on 3 January 2021 and WHO’s listing on 15 February.
- Did announced supply targets prove completed deliveries?
- No. Production, dispatch, international delivery and administration are different milestones.
Primary and institutional sources
How this history was checked
Company, regulator and WHO records establish distinct functions and dates. Independent reporting supplies the export crisis and later resumption. Historical permissions and commitments are not presented as current clinical advice. This article was reviewed on 23 October 2026.
- Serum Institute of IndiaAbout us: Cyrus’s 1966 founding, products, 2012 Bilthoven acquisition and separate leadership offices
- Serum Institute of IndiaMilestones: foundation stone on 12 June 1966 at Hadapsar, Pune
- Villoo Poonawalla FoundationAdar C. Poonawalla: Westminster education, 2001 entry and 2011 CEO succession
- UK Companies HouseSerum Life Sciences register: Adar’s January 1981 birth month and Indian nationality
- Serum Institute of India2026 Earthshot partnership announcement identifies Adar as CEO
- Reuters / EuronewsDecember 2021 Oxford research pledge and distinct Cyrus and Adar roles
- AstraZeneca4 June 2020: Oxford vaccine licence and intended SII manufacturing and supply
- DCGI / Ministry of Health and Family Welfare3 January 2021: restricted emergency permission and continuing Indian trial
- World Health Organization15 February 2021: two AstraZeneca/Oxford products listed for emergency use
- Serum Institute of India12 January 2021: first Covishield shipments leave the plant
- Mint18 May 2021: export interruption, domestic shortage and Poonawalla’s response
- Reuters / The Economic Times21 October 2021: gradual resumption of vaccine exports
- Rudolph.A.furtado / Wikimedia CommonsComplete Indian Derby photograph, own-work claim and CC BY 4.0 grant
- Creative CommonsAttribution 4.0 International licence